The Hemopump™, the first intravascular ventricular assist device

Richard Wampler, O. H. Frazier

Research output: Contribution to journalArticle

Abstract

Development of durable left ventricular assist devices (LVADs), based on rotary flow blood pumps, began in earnest after the successful implantation of a catheter-mounted axial flow blood pump via intravascular access in 1988. This device, the Hemopump, successfully supported the circulation of a patient in cardiogenic shock secondary to acute rejection of a transplanted heart. Duration of support was 46 hours, resulting in complete recovery of cardiac function and hospital discharge. In effect, this sentinel event demonstrated that continuous-flow blood pumps could be used to support patients in cardiogenic shock. This held true in spite of many widely held paradigms against rotary blood pumps regarding blood damage, diminished pulsatility, and thrombosis. At this writing, 50,000 patients have been implanted with durable LVADs based on rotary blood pumps as a bridge to cardiac transplantation or destination support as long as 10 years.

Original languageEnglish (US)
Pages (from-to)297-300
Number of pages4
JournalASAIO Journal
Volume65
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Heart-Assist Devices
Blood
Pumps
Left ventricular assist devices
Cardiogenic Shock
Rotational flow
Axial flow
Catheters
Recovery of Function
Heart Transplantation
Thrombosis
Recovery
Equipment and Supplies

Keywords

  • catheter pump
  • continuous flow
  • Hemopump
  • intravascular pump

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Biomedical Engineering

Cite this

The Hemopump™, the first intravascular ventricular assist device. / Wampler, Richard; Frazier, O. H.

In: ASAIO Journal, Vol. 65, No. 3, 01.03.2019, p. 297-300.

Research output: Contribution to journalArticle

@article{db1b7dc5540a4ef39af4a0a2540dfa10,
title = "The Hemopump™, the first intravascular ventricular assist device",
abstract = "Development of durable left ventricular assist devices (LVADs), based on rotary flow blood pumps, began in earnest after the successful implantation of a catheter-mounted axial flow blood pump via intravascular access in 1988. This device, the Hemopump, successfully supported the circulation of a patient in cardiogenic shock secondary to acute rejection of a transplanted heart. Duration of support was 46 hours, resulting in complete recovery of cardiac function and hospital discharge. In effect, this sentinel event demonstrated that continuous-flow blood pumps could be used to support patients in cardiogenic shock. This held true in spite of many widely held paradigms against rotary blood pumps regarding blood damage, diminished pulsatility, and thrombosis. At this writing, 50,000 patients have been implanted with durable LVADs based on rotary blood pumps as a bridge to cardiac transplantation or destination support as long as 10 years.",
keywords = "catheter pump, continuous flow, Hemopump, intravascular pump",
author = "Richard Wampler and Frazier, {O. H.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/MAT.0000000000000802",
language = "English (US)",
volume = "65",
pages = "297--300",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The Hemopump™, the first intravascular ventricular assist device

AU - Wampler, Richard

AU - Frazier, O. H.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Development of durable left ventricular assist devices (LVADs), based on rotary flow blood pumps, began in earnest after the successful implantation of a catheter-mounted axial flow blood pump via intravascular access in 1988. This device, the Hemopump, successfully supported the circulation of a patient in cardiogenic shock secondary to acute rejection of a transplanted heart. Duration of support was 46 hours, resulting in complete recovery of cardiac function and hospital discharge. In effect, this sentinel event demonstrated that continuous-flow blood pumps could be used to support patients in cardiogenic shock. This held true in spite of many widely held paradigms against rotary blood pumps regarding blood damage, diminished pulsatility, and thrombosis. At this writing, 50,000 patients have been implanted with durable LVADs based on rotary blood pumps as a bridge to cardiac transplantation or destination support as long as 10 years.

AB - Development of durable left ventricular assist devices (LVADs), based on rotary flow blood pumps, began in earnest after the successful implantation of a catheter-mounted axial flow blood pump via intravascular access in 1988. This device, the Hemopump, successfully supported the circulation of a patient in cardiogenic shock secondary to acute rejection of a transplanted heart. Duration of support was 46 hours, resulting in complete recovery of cardiac function and hospital discharge. In effect, this sentinel event demonstrated that continuous-flow blood pumps could be used to support patients in cardiogenic shock. This held true in spite of many widely held paradigms against rotary blood pumps regarding blood damage, diminished pulsatility, and thrombosis. At this writing, 50,000 patients have been implanted with durable LVADs based on rotary blood pumps as a bridge to cardiac transplantation or destination support as long as 10 years.

KW - catheter pump

KW - continuous flow

KW - Hemopump

KW - intravascular pump

UR - http://www.scopus.com/inward/record.url?scp=85064862296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064862296&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000802

DO - 10.1097/MAT.0000000000000802

M3 - Article

VL - 65

SP - 297

EP - 300

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 3

ER -